title: Zoledronic acid in breast cancer: latest findings and interpretations.
abstract: The intravenous nitrogen-containing bisphosphonate zoledronic acid has been shown to block multiple steps in tumor metastasis (e.g. angiogenesis, invasion, adhesion, proliferation) in preclinical and translational studies. Moreover, clinical data from the ABCSG-12 and ZO-FAST trials demonstrate significantly improved disease-free survival with zoledronic acid in the adjuvant breast cancer setting. In contrast to these two trials, recent interim results from the AZURE trial do not show a benefit from adding zoledronic acid to adjuvant therapy in the overall patient population. However, subset analyses of AZURE data show that zoledronic acid significantly improved overall survival in women who were more than 5 years postmenopausal or older than 60 years at baseline. Similarly, subset analyses of the ABCSG-12 trial data demonstrate greater benefits from zoledronic acid treatment in patients who theoretically would have achieved more complete ovarian suppression. These observations, together with the AZURE postmenopausal data, suggest that the endocrine environment may affect the potential anticancer activity of zoledronic acid. Indeed, current data support the possibility that zoledronic acid might be most effective for improving disease-free survival in the adjuvant breast cancer setting in women who are postmenopausal or have endocrine therapy-induced menopause.
authors.affiliation: Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.
authors.forename: Michael
authors.initials: M
authors.lastname: Gnant
references.citation: J Bone Miner Res. 2010 Mar;25(3):492-8
references.pmid: 19653807
references.citation: Aust N Z J Obstet Gynaecol. 1996 Nov;36(4):484-5
references.pmid: 9006841
references.citation: Crit Rev Oncol Hematol. 2011 Feb;77 Suppl 1:S3-S12
references.pmid: 21353178
references.citation: Lancet Oncol. 2008 Sep;9(9):840-9
references.pmid: 18718815
references.citation: J Clin Endocrinol Metab. 2006 May;91(5):1848-54
references.pmid: 16449331
references.citation: Clin Cancer Res. 2008 May 1;14(9):2519-26
references.pmid: 18451212
references.citation: Anticancer Res. 2010 May;30(5):1807-13
references.pmid: 20592383
references.citation: J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78
references.pmid: 18695136
references.citation: Ann N Y Acad Sci. 2010 Mar;1192:153-60
references.pmid: 20392231
references.citation: Gynecol Oncol. 2000 Jan;76(1):126-7
references.pmid: 10620455
references.citation: J Clin Endocrinol Metab. 2008 Oct;93(10):3847-52
references.pmid: 18647803
references.citation: J Clin Oncol. 2008 Apr 1;26(10):1671-6
references.pmid: 18375896
references.citation: Cell. 2009 Dec 24;139(7):1315-26
references.pmid: 20064377
references.citation: Br J Cancer. 2010 Mar 30;102(7):1099-105
references.pmid: 20234364
references.citation: Cancer Treat Rev. 2008 Aug;34(5):453-75
references.pmid: 18423992
references.citation: Crit Rev Oncol Hematol. 2009 Jan;69(1):73-82
references.pmid: 18757208
references.citation: Pediatrics. 2007 Mar;119 Suppl 2:S150-62
references.pmid: 17332236
references.citation: Ann Oncol. 2012 Mar;23(3):597-604
references.pmid: 21551002
references.citation: Proc Natl Acad Sci U S A. 2006 May 16;103(20):7829-34
references.pmid: 16684881
references.citation: Maturitas. 2008 Sep-Oct;61(1-2):67-77
references.pmid: 19434880
references.citation: Breast Cancer Res Treat. 1997 Apr;43(2):183-90
references.pmid: 9131274
references.citation: Cancer Immunol Immunother. 2009 Jan;58(1):31-8
references.pmid: 18458903
references.citation: Clin Breast Cancer. 2009 May;9(2):77-85
references.pmid: 19433387
references.citation: N Engl J Med. 2009 Feb 12;360(7):679-91
references.pmid: 19213681
references.citation: Ann Oncol. 2010 Nov;21(11):2188-2194
references.pmid: 20444845
references.citation: Mol Med. 2011;17(7-8):579-87
references.pmid: 21424106
references.citation: Oncologist. 2008 May;13(5):503-14
references.pmid: 18515735
references.citation: Eur J Cancer. 2009 Jul;45(11):1909-15
references.pmid: 19447606
references.citation: Leukemia. 2008 May;22(5):941-50
references.pmid: 18305549
references.citation: J Clin Oncol. 2001 Jul 15;19(14):3306-11
references.pmid: 11454877
references.citation: J Clin Endocrinol Metab. 1995 Nov;80(11):3351-5
references.pmid: 7593450
references.citation: Lancet Oncol. 2010 May;11(5):421-8
references.pmid: 20362507
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4482-6
references.pmid: 17671133
references.citation: Cancer Res. 2011 Jul 1;71(13):4562-72
references.pmid: 21646473
references.citation: Nat Rev Cancer. 2002 Aug;2(8):584-93
references.pmid: 12154351
references.citation: Ann Oncol. 2009 Aug;20(8):1319-29
references.pmid: 19535820
references.citation: Cancer Res. 2011 Jan 15;71(2):614-24
references.pmid: 21224357
references.citation: Br J Cancer. 2010 Mar 16;102(6):1010-7
references.pmid: 20160726
references.citation: Int J Cancer. 2010 Jan 15;126(2):522-32
references.pmid: 19621384
references.citation: Lancet Oncol. 2011 Jul;12(7):631-41
references.pmid: 21641868
references.citation: Bone. 2011 Feb;48(2):259-66
references.pmid: 20920623
references.citation: Curr Cancer Drug Targets. 2009 Nov;9(7):824-33
references.pmid: 20025570
references.citation: Nat Med. 2006 Aug;12(8):875-8
references.pmid: 16892025